IL178094A - Enantiomers, their use in the treatment or prevention of viral diseases, allergic immune diseases, autoimmune diseases or graft rejection, and methods of preparation of these substances - Google Patents

Enantiomers, their use in the treatment or prevention of viral diseases, allergic immune diseases, autoimmune diseases or graft rejection, and methods of preparation of these substances

Info

Publication number
IL178094A
IL178094A IL178094A IL17809406A IL178094A IL 178094 A IL178094 A IL 178094A IL 178094 A IL178094 A IL 178094A IL 17809406 A IL17809406 A IL 17809406A IL 178094 A IL178094 A IL 178094A
Authority
IL
Israel
Prior art keywords
organ
prevention
treatment
methods
making same
Prior art date
Application number
IL178094A
Other languages
English (en)
Hebrew (he)
Other versions
IL178094A0 (en
Inventor
Shmuel Bittner
Eliahu Kaplan
Eliakim Harlev
Original Assignee
Shmuel Bittner
New Era Biotech Ltd
Eliahu Kaplan
Eliakim Harlev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shmuel Bittner, New Era Biotech Ltd, Eliahu Kaplan, Eliakim Harlev filed Critical Shmuel Bittner
Publication of IL178094A0 publication Critical patent/IL178094A0/en
Publication of IL178094A publication Critical patent/IL178094A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Polyethers (AREA)
IL178094A 2004-03-26 2006-09-14 Enantiomers, their use in the treatment or prevention of viral diseases, allergic immune diseases, autoimmune diseases or graft rejection, and methods of preparation of these substances IL178094A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55708704P 2004-03-26 2004-03-26
PCT/IB2005/001160 WO2005092305A2 (en) 2004-03-26 2005-03-24 Compounds for treating aids and other diseases

Publications (2)

Publication Number Publication Date
IL178094A0 IL178094A0 (en) 2006-12-31
IL178094A true IL178094A (en) 2015-02-26

Family

ID=34969419

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178094A IL178094A (en) 2004-03-26 2006-09-14 Enantiomers, their use in the treatment or prevention of viral diseases, allergic immune diseases, autoimmune diseases or graft rejection, and methods of preparation of these substances

Country Status (7)

Country Link
US (3) US7674829B2 (https=)
EP (1) EP1750691B1 (https=)
JP (1) JP4939396B2 (https=)
AU (1) AU2005225239B2 (https=)
CA (1) CA2560922C (https=)
IL (1) IL178094A (https=)
WO (1) WO2005092305A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1546088B1 (en) * 2002-10-03 2014-12-17 Novaremed Ltd. Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
DE102004025220A1 (de) * 2004-05-22 2005-12-08 Bayer Cropscience Gmbh Ölsuspensionskonzentrat
JP4939396B2 (ja) * 2004-03-26 2012-05-23 ノヴァレメッド リミテッド Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法
EP2397148A3 (en) 2006-02-02 2012-04-25 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
EP2026775B1 (en) * 2006-05-09 2015-04-29 Novaremed Ltd. Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
GB0804213D0 (en) 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
EP2475361B1 (en) * 2009-09-09 2019-11-06 Novaremed Ltd. N-substituted benzenepropanamides for use in the treatment of pain and inflammation
US8802734B2 (en) * 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
GB201116335D0 (en) * 2011-09-21 2011-11-02 Novaremed Ltd A method of treating or preventing affective disorders
DK2788317T3 (da) * 2011-12-08 2020-01-20 Novaremed Ltd Isolerede stereoisomere former af (S)2-N(3-O-((S)propan-2-ol)-1-propyl-4-hydroxybenzen)-3-phenylpropylamid
CN113329746B (zh) 2019-01-23 2025-05-02 诺瓦麦有限公司 用于治疗或预防疼痛、炎症和/或自身免疫的化合物
EP3939578A1 (en) * 2020-07-13 2022-01-19 Novaremed Ltd. Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
WO2026037478A1 (en) 2023-08-11 2026-02-19 Novaremed AG (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2908691A (en) * 1958-07-14 1959-10-13 Searle & Co Hydroxyphenalkylaminoalkylindoles and ethers corresponding thereto
ZA732136B (en) 1972-04-12 1974-03-27 Lilly Co Eli Dopamine derivatives
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4908322A (en) * 1985-09-06 1990-03-13 The United States Of America As Represented By The Department Of Health And Human Services Derivatization of amines for electrochemical detection
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
AU1463997A (en) 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
EP0887340A4 (en) 1996-02-06 2000-03-29 Japan Tobacco Inc CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE
WO2002046176A1 (en) 2000-12-05 2002-06-13 Nippon Chemiphar Co., Ltd. Ppar (peroxisome proliferator activated receptor) activators
EP1546088B1 (en) * 2002-10-03 2014-12-17 Novaremed Ltd. Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
JP4939396B2 (ja) 2004-03-26 2012-05-23 ノヴァレメッド リミテッド Ａｉｄｓ及び他のウイルス性疾患及びｈｉｖ関連感染症の改善又はその治療用化合物及びそのような化合物を含む組成物、そのような疾患及び感染症の治療方法及びそのような化合物及び組成物の製造方法
RU2309144C2 (ru) 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств
EP2026775B1 (en) 2006-05-09 2015-04-29 Novaremed Ltd. Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders
AU2008302356A1 (en) 2007-09-17 2009-03-26 Academia Sinica Compositions and methods for treating inflammation and inflammation-related disorders by Plectranthus Amboinicus extracts
GB0804213D0 (en) 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
CN101503370B (zh) 2009-03-02 2012-08-22 上海应用技术学院 一种n-环丙基-反-2-顺-6-壬二烯酸酰胺的合成方法
CN101503373B (zh) 2009-03-13 2013-07-24 山东大学 2-氨基-1-(4-硝基苯基)-1-乙醇类金属蛋白酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
IL178094A0 (en) 2006-12-31
US8252843B2 (en) 2012-08-28
WO2005092305A2 (en) 2005-10-06
US7754771B2 (en) 2010-07-13
AU2005225239B2 (en) 2012-06-14
US20060148874A1 (en) 2006-07-06
AU2005225239A2 (en) 2005-10-06
EP1750691A2 (en) 2007-02-14
EP1750691B1 (en) 2016-08-10
CA2560922A1 (en) 2005-10-06
JP2007531717A (ja) 2007-11-08
AU2005225239A1 (en) 2005-10-06
WO2005092305A3 (en) 2006-03-02
US20100331383A1 (en) 2010-12-30
JP4939396B2 (ja) 2012-05-23
CA2560922C (en) 2014-01-07
US7674829B2 (en) 2010-03-09
US20050239898A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
IL291162A (en) Isolated human rpe cells and their use for the treatment of retinal degenerative diseases
SI1546088T1 (sl) Spojine za uporabo v zdravljenju avtoimunskih bolezni, imunoalergijskih bolezni in zavrnitve transpalantata organa ali tkiva
EP1916964A4 (en) IMPLANTS AND METHODS FOR THE REPAIR, REPLACEMENT AND TREATMENT OF JOINT DISEASES
PL1979050T3 (pl) Leczenie chorób naczyń obwodowych z zastosowaniem komórek pochodzenia poporodowego
EP1737453A4 (en) METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS
ZA200801511B (en) Novel diazaspiroalkanes and their use for treatment of CCR8 medicated diseases
EP1740262A4 (en) MICRO-SURGERY TISSUE TREATMENT SYSTEM
EP1853394A4 (en) SURFACE TREATMENT METHOD FOR IMPLANTS MANUFACTURED IN TITANIUM OR TITANIUM ALLOY
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
EP1732484A4 (en) OPHTHALMIC IMPLANT FOR THE TREATMENT OF GLAUCOMA
IL178094A (en) Enantiomers, their use in the treatment or prevention of viral diseases, allergic immune diseases, autoimmune diseases or graft rejection, and methods of preparation of these substances
TWI372056B (en) Novel medicament combinations for the treatment of respiratory diseases
EP2091480A4 (en) SYSTEM FOR THE TREATMENT OF HEART TISSUE
GB0410399D0 (en) The treatment of respiratory disease
IL178815A0 (en) The treatment of respiratory disease
EP1838260A4 (en) SYSTEM AND METHOD FOR TREATMENT OF CARDIAC TISSUE
EP1773882A4 (en) DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH SIGLEC-6
GB0523961D0 (en) The treatment of ophthalmic diseases
EP1740221A4 (en) METHOD AND COMPOSITIONS FOR TREATING POLYCYSTIC DISEASES
EP1664775A4 (en) COMPOSITION FOR THE DIAGNOSIS OF RETINAL VASCULAR DISEASE COMPRISING ALDOLASE AND DIAGNOSTIC METHOD USING THE SAME
EP1781318A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYKYSTIC DISEASES
GB0523964D0 (en) The treatment of ophthalmic diseases
EP1846013A4 (en) TREATMENT OF SKIN DISEASES
HK1099210A (en) Protein kinase c inhibitors for the treatment of autoimmune diseases and of transplant rejection

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed